Skip to main content

Open Access Transient hypogammaglobulinemia and severe atopic dermatitis: Open-label treatment with immunoglobulin in a case series

Download Article:
 Download
(HTML 30.6904296875 kb)
 
or
 Download
(PDF 51.6171875 kb)
 
Background:

We reported on six infants between 5 and 11 months old, with transient hypogammaglobulinemia of infancy and severe refractory atopic dermatitis, who were treated with open-label immunoglobulin (Ig) after conventional therapy failed. All six infants had an IgG level of <225 mg/dL, elevated eosinophil and IgE levels, and no urine or stool protein losses, but they did exhibit hypoalbuminemia.

Objective:

To evaluate the utility of open-label immunoglobulin in infants with severe atopic dermatitis for whom conventional therapy failed. We reviewed the clinical utility of intravenous immunoglobulin in the treatment of severe atopic dermatitis, the most recent research in the field, and suggested mechanisms for its benefit.

Methods:

The six infants were identified from a retrospective chart review at the University of California Los Angeles Allergy and Immunology outpatient pediatric clinic.

Results:

All six patients were treated with 400 mg/kg/month of intravenous immunoglobulin and had normalization of their IgG and albumin levels, and all but one had clinically improved atopic dermatitis.

Conclusion:

Infants with severe atopic dermatitis who did not respond to conventional therapy avoidance may benefit from intravenous immunoglobulin therapy.

8 References.

No Supplementary Data.
No Article Media
No Metrics

Keywords: Immunoglobulin; allergic rhinitis; asthma; atopic dermatitis; atopy; eosinophilia; food allergy; hypogammaglobulinemia; protein loss; transient hypogammaglobulinemia of infancy

Document Type: Research Article

Publication date: 2016-01-01

More about this publication?
  • In the fields of rhinology & allergy, as in all medical fields, there is a need for a greater number of journals which publish in the open access format. The underlying spirit of this format is to break down the barriers to knowledge sharing. Allergy & Rhinology, was created to serve this need; and is proud to take the lead in publishing quality research work as an experiment in the open format. As long as the fiscal model works, the Journal shall allow all users the right to freely read, download, copy, distribute, print, search, or link to the full texts of its articles.

    The academic standard of Allergy & Rhinology is designed to be no different than traditional subscription-based, scientific and scholarly journals in that the quality of the research work which it publishes shall meet the rigors of peer-review and other scholarly quality controls.

  • Information for Authors
  • www.AJRA.com
  • www.AllergyandAsthmaProceedings.com
  • www.NARAConference.org
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more